Santomasso, Bianca

Publications

Sort by

Co-Author Network

selected publications

Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan. CNS oncology. 2022 Academic Article GET IT
Times cited: 1
Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force. Transplantation and cellular therapy. 2022 Review GET IT
Times cited: 5
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2022 Review GET IT
Times cited: 55
Reply to M.B. Abid. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Letter GET IT
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood cancer journal. 2022 Academic Article GET IT
Times cited: 26
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Review GET IT
Times cited: 59
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. 2021 GET IT
Times cited: 296
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood advances. 2021 Academic Article GET IT
Times cited: 34
Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2021 Academic Article GET IT
Times cited: 28
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. Journal for immunotherapy of cancer. 2021 Academic Article GET IT
Times cited: 53
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. Transplantation and cellular therapy. 2021 Conference Paper GET IT
Times cited: 34
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. Journal for immunotherapy of cancer. 2021 Academic Article GET IT
Times cited: 180
Neurotoxicity Biology and Management. Cancer journal (Sudbury, Mass.). 2021 Review GET IT
Times cited: 4
Clinical trial of proton craniospinal irradiation for leptomeningeal metastases. Neuro-oncology. 2021 Academic Article GET IT
Times cited: 30
Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients. Cancer cell. 2021 Academic Article GET IT
Times cited: 36
Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma. Haematologica. 2021 Letter GET IT
Times cited: 24
The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy. Transplantation and cellular therapy. 2020 Academic Article GET IT
Times cited: 14
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 106
Inflammatory leptomeningeal cytokines mediate delayed COVID-19 encephalopathy. medRxiv : the preprint server for health sciences. 2020 Article GET IT
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood advances. 2020 Academic Article GET IT
Times cited: 109
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood cancer journal. 2020 Academic Article GET IT
Times cited: 98
Reply. Ophthalmology. 2020 Letter GET IT
Times cited: 1
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood advances. 2020 Academic Article GET IT
Times cited: 45
Anticancer Drugs and the Nervous System. Continuum (Minneapolis, Minn.). 2020 Review GET IT
Times cited: 13
Immune Checkpoint Inhibitor-Associated Optic Neuritis. Ophthalmology. 2020 Academic Article GET IT
Times cited: 18
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. 2020 GET IT
Times cited: 218
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood advances. 2020 Academic Article GET IT
Times cited: 81
MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors. Neuro-oncology. 2019 Academic Article GET IT
Times cited: 33
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy. 2019 GET IT
Times cited: 46
The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2019 Review GET IT
Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2019 Academic Article GET IT
Times cited: 35
Reply. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2019 Letter GET IT
Management of Immunotherapy-Related Toxicities, Version 1.2019. 2019 GET IT
Times cited: 324
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Conference Paper GET IT
Times cited: 1231
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer discovery. 2018 Academic Article GET IT
Times cited: 478
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. 2018 GET IT
Times cited: 2162
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 1524
T cells presenting viral antigens or autoantigens induce cytotoxic T cell anergy. JCI insight. 2017 Academic Article GET IT
Times cited: 3
T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation. European journal of immunology. 2014 Academic Article GET IT
Times cited: 24
Temporal lobe meningioma with ipsilateral herpes simplex encephalitis. The Neurohospitalist. 2014 Academic Article GET IT
Tolerance to the neuron-specific paraneoplastic HuD antigen. PloS one. 2009 Academic Article GET IT
Times cited: 23
A T-cell receptor associated with naturally occurring human tumor immunity. 2007 GET IT
Times cited: 32
G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature. 1998 Academic Article GET IT
Times cited: 753

more ...

less ...

Background

education and training

M.D., Weill Cornell Medical College, Cornell University 2008
Ph.D., The Rockefeller University 2007
B.S., Yale University 1994

Contact

full name

Bianca Santomasso

VIVO Weill Cornell Medical College

Bianca Santomasso Assistant Professor of Neurology

Publications

selected publications

Background

education and training

Contact

full name